Related Experiment Video

Updated: Jul 4, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Novel Pharmacotherapies for Hyperlipidemia

Brian V Reamy1, Brian Ford2, Charles Goodman2

  • 1Academic Affairs, Uniformed Services University School of Medicine, 4301 Jones Bridge Road, Bethesda, MD 20814, USA.

Primary Care
|January 26, 2024
PubMed

Insights

This review covers standard, new, and emerging treatments for hyperlipidemia, focusing on managing cholesterol and triglycerides to prevent cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Established link between dyslipidemia (high LDL-C, low HDL-C, high triglycerides) and cardiovascular disease (CVD) risk.
  • Numerous agents have been developed and tested for dyslipidemia treatment over decades.
  • The efficacy of many established treatments in reducing CVD morbidity and mortality is well-defined.

Purpose of the Study:

  • To review current standard treatments for hyperlipidemia.
  • To discuss recently approved and novel therapeutic agents for dyslipidemia.
  • To explore emerging treatments for the primary and secondary prevention of CVD by managing dyslipidemia.

Main Methods:

  • Literature review of clinical trials and pharmacological studies.
  • Analysis of data on efficacy and safety of lipid-lowering agents.
  • Synthesis of information on established, new, and investigational therapies.

Main Results:

  • Standard therapies effectively manage dyslipidemia and reduce CVD risk.
  • Newer agents offer improved efficacy and tolerability profiles.
  • Emerging treatments show promise for enhanced CVD prevention through advanced lipid management.

Conclusions:

  • Comprehensive management of dyslipidemia is crucial for cardiovascular health.
  • A range of therapeutic options exists, from standard to novel and emerging agents.
  • Continued research and development are vital for optimizing CVD prevention strategies.

Keywords:
Cardiovascular diseaseHyperlipidemiaLipoprotein(a)Novel therapeuticsPrimary preventionSecondary prevention

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

1.1K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
515
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
44
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
234
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323